不同年龄对阿替普酶静脉溶栓治疗急性脑梗死的临床疗效和预后影响

Clinical efficacy of Alteplase intravenous thrombolysis on patients with acute cerebral infarction at different ages and prognosis effect analysis

目的探讨分析不同年龄对阿替普酶静脉溶栓治疗急性脑梗死的临床疗效和预后影响。方法于本院2012年10月—2013年10月医治的急性脑梗死患者中,选取86例予以0.9 mg/kg阿替普酶静脉溶栓治疗,并根据其年龄大小而分为低龄组43例(年龄<60岁)和高龄组43例(年龄≥60岁),对比分析两组的临床疗效及预后情况。结果治疗后,低龄组患者NIHSS、mRS评分均有所降低,且明显低于高龄组,差异比较有显著统计学意义(P<0.01);并且,治疗后,低龄组完全恢复率、溶栓直接并发症和非直接并发症发生率分别为13.95%、2.33%、18.60%,而高龄组则分别为0.00%、16.28%、79.07%,两组差异比较有统计学意义(P<0.05)。结论阿替普酶静脉溶栓治疗急性脑梗死效果显著,但低龄患者的临床疗效及预后明显优于高龄患者,且并发症更少,更具临床推广价值。

Objective ： To discuss and analyze clinical efficacy of alteplase intravenous thrombolysis on patients with acute cerebral infarction at different ages and prognosis effect. Methods： Eighty-six patients with acute cerebral infarction treated in our hospital from October 2012 to October 2013 were selected to conduct 0.9mg/kg alteplase intravenous thrombolytic therapy, the selected patients was divided into two groups according to their age, the younger group 43 （ Age 〈 60 years） and senior age group （age ≥ 60 years）, and the clinical curative effect and prognosis of the two groups were compared and analyzed. Resalts ： After treatment, the NIHSS and mRS scores of the younger group were significantly lower than those of the elderly group （P 〈 0.01 ）. Moreover, after treatment, the complete recovery rate, thrombolytic direct complications and indirect complications of the young group （13.95%, 2.33% and 18.60% respectively） were significantly lower than the elderly group （ 0. 00%, 16. 28% and 79. 07% respectively）, the difference between two groups had statistical significance （P 〈 0. 05）. Conclusion： Aheplase intravenous thrombolytic therapy of acute cerebral infarction is significant, but the clinical efficacy and prognosis of young patients is significantly better than the elderly patients, and has less complications, which has more clinical value.